Mavyret and Prezista

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Darunavir may significantly increase the blood levels of glecaprevir. This may increase the risk of liver problems that can occasionally occur during treatment with glecaprevir. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact. You should seek immediate medical attention if you have fever, chills, joint pain or swelling, unusual bleeding or bruising, skin rash, itching, loss of appetite, fatigue, nausea, vomiting, abdominal pain, dark urine, pale stools, and/or yellowing of the skin or eyes, as these may be signs and symptoms of liver damage. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

GENERALLY AVOID: Coadministration with darunavir/ritonavir or lopinavir/ritonavir may significantly increase the plasma concentrations of glecaprevir. The proposed mechanism is inhibition of organic anion transporting polypeptide (OATP) 1B1-mediated hepatic uptake of glecaprevir by darunavir, lopinavir, and ritonavir. Inhibition of P-glycoprotein-mediated intestinal efflux and CYP450 3A4-mediated metabolism of glecaprevir may also contribute. When glecaprevir-pibrentasvir 300 mg-120 mg once daily was administered with darunavir 800 mg plus ritonavir 100 mg once daily to 8 study subjects, glecaprevir peak plasma concentration (Cmax), systemic exposure (AUC) and trough plasma concentration (Cmin) increased by approximately 3.1-, 5.0- and 8.2-fold, respectively. Pibrentasvir Cmax and AUC were unaffected, but Cmin increased by approximately 1.7-fold. Darunavir and ritonavir pharmacokinetics were also impacted, with darunavir Cmax and AUC increasing by approximately 1.3-fold each and ritonavir Cmax and AUC increasing by approximately 2-fold each. When glecaprevir-pibrentasvir 300 mg-120 mg once daily was administered with lopinavir-ritonavir 400 mg-100 mg twice daily to 9 study subjects, glecaprevir Cmax, AUC and Cmin increased by approximately 2.6-, 4.4- and 18.6-fold, respectively, while pibrentasvir Cmax, AUC and Cmin increased by 1.4-, 2.5- and 5.2-fold, respectively. High plasma levels of glecaprevir may increase the risk of adverse effects such as alanine aminotransferase (ALT) and bilirubin elevations.

MANAGEMENT: Concomitant use of glecaprevir with darunavir or lopinavir plus ritonavir is not recommended.

Mavyret

Generic Name: glecaprevir / pibrentasvir

Brand name: Mavyret

Synonyms: n.a.

What is Mavyret?

Prezista

Generic Name: darunavir

Brand name: Prezista

Synonyms: n.a.

What is Prezista?